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Abstract
Background: Oral HPV infections detected six-months apart were compared to those detected bi-weekly, in an HIV-positive
cohort, during the intervening months to elucidate systematic biases introduced into natural history studies by sampling
interval.
Methods: Fourteen consecutive oral rinse samples were collected every two weeks for six months from an HIV-positive
cohort (n=112) and evaluated for the presence of 37 HPV types. The cumulative probability of type-specific HPV detection
at visits 1 through 14 was determined as a function of infection categorized at visits 1 and 14 as persistent, newly detected,
cleared or absent. Transition models were used to evaluate the effect of HPV viral load (measured by RT-PCR for HPV 16, 18,
31, 33, 35) on infection persistence.
Results: The average point prevalence of oral HPV infection was similar at two-week and six-month sampling intervals (45%
vs. 47%, p=0.52), but cumulative prevalence was higher with the former (82% vs. 53%, p,0.001) as was the cumulative
prevalence of type-specific infections (9.3% vs 3.8%, p,0.0001). Type-specific infections persistent under a six-month
sampling interval had a high probability (0.93, 95%CI 0.83–0.98) of detection at 50% or more of the intervening visits and
infections that were absent had a high probability (0.94, 95% CI 0.93–0.95) of no interval detection. The odds of detection at
any visit significantly increased for each unit increase in HPV viral load at the previous visit.
Conclusions: Six-month sampling is appropriate to model factors associated with type-specific oral HPV infection
persistence but may misclassify HPV-exposed individuals as unexposed.
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Introduction
Oral human papillomavirus (HPV) 16 infection is strongly
associated with oropharyngeal squamous cell carcinoma
(OPSCC)[1]. Moreover, seropositivity to HPV16 elevates risk for
development of OPSCC[2]. Although consistent with a temporal
link between oral HPV infection and development of OPSCC,
oral HPV natural history studies have not been reported. Such
studies will be critical for clarifying potential use of oral HPV
detection in OPSCC screening programs.
An important factor for HPV natural history studies is the
sampling interval, and six-month sampling intervals are commonly
used for cervical studies. We have previously evaluated the feasibility
of a six-month sampling interval for oral HPV infection[3].
However, a recent natural history study of cervical HPV infection
among adolescent women using a two-week sampling interval
revealed short-lived infections (, lasting six-month) were common.
Asaconsequence,thecumulativeprevalencewashigherinthisstudy
relative to prior studies in similar populations[4].
We performed a short-term natural history study of oral HPV
infections to compare the results of a two-week to a six-month
sampling interval to identify potential systematic biases introduced
into natural history studies by the frequency of sampling. Oral
HPV infections refers to infections of the oral cavity and
oropharynx. An HIV-positive cohort, known to be at elevated
risk for oral HPV infection and related malignancies, was selected
as our study population.
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. This study was approved by the
Institutional Review Board of Johns Hopkins Hospital (application
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11918number 03-11-24-04). All patients provided written informed
consent for the collection of samples and subsequent analysis.
Study population
A convenience sample of 112 HIV-positive patients from the
Johns Hopkins Hospital was recruited during March 2005.
Eligibility criteria included known HIV-positive status and
willingness to comply with bi-monthly (every two week) visits for
six months. Enrollment took into consideration both CD4 count
(, or $200 cells per mL) and gender to result in a study population
with approximately equal proportions. Subjects received monetary
compensation ($160) for participation.
Procedures
Oral rinse samples were collected every two weeks for six
consecutive months (visits 1–14) using a 30 second Scope
TM
mouthwash rinse and gargle[5]. A self-administered questionnaire
was completed at enrollment for measurement of baseline
characteristics, however interval behavioral data were not
ascertained. Venous blood was collected at visits one and 14 for
measurement of CD4 count and HIV viral load. A Scope
TM
sample was collected per 20 rinse samples and processed similarly
as a contamination control.
Laboratory analysis
Oral exfoliated cells were separated by centrifugation, washed,
and re-suspended with phosphate buffered saline and stored at
280uC.
DNA was purified by use of a modified protocol for Puregene
DNA Purification (Gentra Systems, Minneapolis, MN)[5]. The
presence of HPV genomic DNA of 37 HPV types (Low-risk types
6, 11, 38, 40, 42, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 81, 83, 84,
89; High-risk types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56,
58, 59, 66, 68, 73, 82[6]) was detected by PGMY09/11 L1
consensus primer PCR[7], and type-specified by hybridization to a
prototype line blot (Roche Molecular Systems, Inc., Alameda,
California). Samples positive for b-globin were evaluable, scored as
negative or positive, and the HPV type(s) detected reported for
positive samples.
HPV viral load for types 16, 18, 31, 33, and 35, chosen because
of their association with OPSCC[8], was measured for all samples
collected from individuals ever positive by line blot hybridization
for the corresponding HPV type(s). Type-specific, Taq-Man, real-
time PCR (Applied Biosystems, Foster City, CA) assays were
performed as previously described[9,10]. Each sample, including
the standards, was assayed in duplicate, and a duplicate mean $
one copy of viral DNA was positive. To adjust oral HPV viral load
to the number of oral epithelial cells present per PCR-reaction (see
below), cell number was estimated by use of a TaqMan real-time
PCR targeting a single copy human gene on chromosome 7,
Human Endogenous Retrovirus 3 (ERV-3)[11,12].
HIV viral load was measured by use of the Roche AMPLI-
COR
TM HIV-1 Monitor Test, version 1.5 and reported from
,400 to 750,000 copies per mL. CD4 cell counts were measured
by use of the Beckton Dickenson BD TriTest CD4 FITC/CD8
PE/CD3 PerCP Reagent and reported as the number of CD4
+
cells per microliter of blood (absolute count).
Statistical analysis
Descriptive statistics were used to report demographic,
biological and behavioral characteristics of the study population
and to compare subjects who completed the study, defined as
having attended visits one to 14 with a maximum of one interval
missed visit, to those who were lost to follow-up. HPV infection
status was determined at visits one through 14 and evaluated both
in terms of individuals and for type-specific infections. In analysis
by individual, a subject was considered infected if one or more of
the 37 HPV types evaluated were detected at each visit (point
prevalence) or detected in any of the samples collected over the
course of the study (cumulative prevalence). In analysis by
infection, presence of each of the 37 type-specific HPV infections
was evaluated for each individual at each visit (point prevalence) or
in any of the samples collected over the course of the study
(cumulative prevalence).
Point and cumulative prevalence of oral HPV (and exact
binomial 95% confidence intervals (CI)) were calculated for visits
one through 14. Average point prevalence represented the
weighted average of point prevalence for each visit, using the
number of individuals or infections at a given visit as the weight.
McNemar’s test was used to compare the two-week and six-month
cumulative prevalence estimates.
The primary goal was to evaluate HPV infection patterns over
time, specifically to compare two-week to six-month sampling
intervals. These analyses were restricted to the 91 individuals who
completed the study. Under the six-month sampling interval, type-
specific HPV infections were categorized as ‘‘persistent’’ (+/+)i f
present at both visit one and 14, ‘‘newly detected’’ (2/+) if absent
at visit one and present at visit 14, ‘‘cleared’’ (+/2) if present at
visit one and absent at visit 14 or ‘‘absent’’ (2/2) if not detected at
either visits one or 14. These categories were distinct from those
for the two-week sampling intervals in which infections were
categorized as ‘‘persistent’’ if present in two or more consecutive
visits, ‘‘transient’’ if detected without persistence, and ‘‘absent’’ if
never detected. A persistent infection was considered ‘‘cleared’’ if
not detected for at least two consecutive visits. An infection was
defined as having ‘‘recurred’’ if it was detected at any visit after
clearance.
To evaluate the relationship between HPV viral load and
infection persistence, the adjusted HPV viral load for types 16, 18,
31, 33, and 35 was plotted across visits. The adjusted HPV viral
load was the logarithmically converted ratio of (10
5) HPV copy
number (as measured by real-time PCR) divided by the number of
cells in the sample (as measured by ERV-3 real-time PCR). A
logistic transition model was used to evaluate the relationship
between the magnitude of the adjusted viral load at one visit and a
positive (i.e. non-zero) adjusted viral load at the next visit.
Results
Study population
The characteristics of the study population are shown in
Table 1. Ninety-one of 112 (81%) individuals completed the six-
month study. Of these, 74 completed all 14 visits and 17 missed a
single visit. The median number of visits for the 21 individuals lost
to follow-up was 10 (interquartile range: 4–12). There were no
significant differences between patients who completed the study
and those lost to follow-up (Table 1).
HPV detection
In total, 1,434 of 1,568 (91%) scheduled visits were completed.
Almost all (1,432 of 1,434 (99.9%)) oral rinse samples were b-
globin positive. All controls for specimen collection and processing
were appropriately negative for HPV and b-globin.
Point and cumulative prevalence of oral HPV
First, we determined the proportion of the study population that
had an oral HPV infection. The point prevalence for oral HPV
Natural History Oral HPV
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relatively stable (range, 32–54%, Figure 1A). Average point
prevalence for the two-week and six-month sampling intervals
was similar (45%, versus 47%, P=0.52) (Table 2 and Figure 1A).
However, cumulative oral HPV prevalence, a measure of
cumulative oral HPV exposure over the course of the study, was
significantly higher with a two-week than a six-month sampling
interval (82.1 versus 53%, P,0.0001, Figure 1B and Table 2).
We then evaluated type-specific oral HPV infections among the
entire study population. We considered all possible infections, i.e.
37 infections from visits 1–14 (a total of 1, 434 evaluable samples)
in 112 individuals (Table 2). The average point prevalence was
similar for the two-week and six-month sampling intervals (3.0%
versus 2.9%, P=0.59). However, cumulative prevalence of
detection of 37 type-specific infections was significantly higher
with a two-week than a six-month sampling interval (9.3%
(n=386 infections) versus 3.8 (n=158 infections), P,0.0001). The
average point prevalence for each of the 37 type-specific infections
ranged from 2.1–3.9% at the two-week sampling intervals (Table 3,
data only shown for HPV types 16, 18, 31, 33, 35).
For HPV16 infection, the average point prevalence was 5.9%
(95% CI: 4.6, 7.2) and the cumulative prevalence was 21.4% (95%
CI: 14.2, 30.2). HPV infections with the highest point prevalence
(pp) and cumulative prevalence (cp) were HPV39 (pp=12%,
cp=28%), HPV52 (pp=8%, cp=21%), HPV35 (pp=6%,
cp=21%) and HPV16 (pp=6%, cp=21%).
Patterns of HPV infection
The patterns of HPV infection were evaluated for both two-
week and six-month sampling intervals among the 91 individuals
who completed visits 1 and 14 (Figure 2). Among these 91
individuals, we evaluated a total of 3,365 possible infections, i.e. 37
HPV types among 91 individuals, minus two samples missing data
on one HPV type or (37691) 22=3,365.
Six-month sampling results. At visit one, 88 HPV
infections were detected in 41 of 91 (45%) participants. At the
final visit, 69 (78%) were categorized as persistent and 19 (22%)
were categorized as cleared (Figure 2), and 56 infections were
newly detected. The remaining 3,221 infections (96% of all
possible infections) were absent at visit one and 14 (Figure 2).
Two-week sampling results. As would be expected, the
number of infections detected with a two-week sampling interval
was higher than for a six-month sampling interval (Figure 2). In
total, 338 of 3,365 (10%) possible infections were detected. By the
two-week sampling definition, 194 were transient, 144 were
persistent, and 59 (41%) of these persistent infections were
categorized as cleared. Of the infections that cleared, 42 (71%)
recurred, 27 (46%) of which again met criteria for persistence. The
median percentage of visits an infection was detectable was 14%
(range, 7–100%), and 83 infections (25%, CI: 20–30%) were
detectable for the majority (.50%) of visits. Only 24 of 144
persistent infections under a two-week definition were detectable
at all subject visits.
Comparison of sampling schemas. We then compared the
HPV detection results obtained with a two-week to a six-month
sampling interval (Figure 2). Almost all (65 of 69, 94%) infections
categorized as persistent under the six-month definition were
persistent under the two-week definition. Similarly, almost all
(3,027 of 3,221, 94%) infections categorized as absent under the
six-month definition were also absent under the two-week
definition. The majority of the 194 additional infections detected
with a two-week sampling interval were transient.
We evaluated the probability that an infection was detectable
for a certain percentage of the two-week visits stratified by their
categorization under the six-month sampling interval as persistent,
cleared, newly detected or absent (Figure 3). Oral HPV infections
defined as persistent under the six-month sampling interval had a
high probability (0.93, 95% CI: 0.83, 0.98) of being detected at
more than 50% of the two-week visits. Similarly, there was very
low probability (0.002, 95% CI: 0.00, 0.004) that oral HPV
Table 1. Characteristics of the total study population and
stratified by follow-up status.*
Total
N=112
Completed
V1-14 N=91
Lost to Follow-
up N=21
Age
Mean (SD) 45 (6.9) 44 (7.0) 46 (6.4)
Median (Range) 40 (28–61) 44 (28–60) 45 (37–61)
Gender N (%)
Male 65 (58%) 54 (59%) 11 (52%)
Female 47 (42%) 37 (41%) 10 (48%)
Race
Caucasian 8 (7%) 6 (7%) 2 (10%)
African 98 (88%) 79 (86%) 19 (90%)
American 6 (5%) 6 (7%) -
Other - - -
Socioeconomic
Status
,10K 65 (58%) 52 (57%) 13 (62%)
10–19K 17 (15%) 14 (15%) 3 (14%)
$20K 12 (10%) 8 (9%) 4 (19%)
Unknown 18 (16%) 17 (19%) 1 (5%)
Present
Marijuana Use
Yes 30 (27%) 21 (23%) 9 (43%)
No 82 (73%) 70 (77%) 12 (57%)
Present
Tobacco Use
Yes 72 (64%) 55 (60%) 17 (81%)
No 39 (35%) 35 (39%) 4 (19%)
Unknown 1 (1%) 1 (1%) -
Heroin Use
Yes 61 (54%) 47 (52%) 14 (67%)
No 51 (46%) 44 (48%) 7 (33%)
Enrollment
CD4 Count
Mean (SD) 341 (275) 328 (237) 396 (403)
Median (Range) 282 (4.0–1251) 290 (4.0–1080) 200 (14–1251)
$200 67 (60%) 57 (63%) 10 (48%)
,200 45 (40%) 34 (37%) 11 (52%)
Enrollment
HIV Viral Load
Undetectable (,400) 47 (42%) 39 (43%) 8 (38%)
400–20,000 25 (22%) 21 (23%) 4 (19%)
$20,000 38 (34%) 29 (32%) 9 (43%)
Unknown 2 (2%) 2 (2%) -
SD = standard deviation.
doi:10.1371/journal.pone.0011918.t001
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more than 50% of intervening visits. Indeed, if a type-specific
HPV infection was not detected at either visit 1 or 14, the
probability that the infection was not detected with a two-week
sampling interval was 0.94 (95% CI: 0.93, 0.95). Probabilities for
cleared and newly detected infections were largely indistinguish-
able. The likelihood that a cleared or newly detected infection by
the six-month sampling interval definition was detectable at 50%
or more of the two-week visits was equivalent (0.26 and 0.25,
respectively).
Figure 1. Point and cumulative prevalence of oral HPV infections in the study population. (a) The average point prevalence for oral HPV
infections among individuals at visits 1 through 14 for all HPV types (solid line) and for HPV16 only (dashed line). A dotted grey horizontal line is
drawn at 43%, the average point prevalence across visits. B) Cumulative prevalence inclusive of visits 1 through 14 for all HPV types (solid line) and for
HPV16 only (dashed line).
doi:10.1371/journal.pone.0011918.g001
Table 2. Average point and cumulative prevalence rates for oral HPV infection by individuals or type-specific infection in two-
week or six-month sampling intervals.
BY INDIVIDUAL BY INFECTION
Average Point Prevalence Cumulative Prevalence Average Point Prevalence
1 Cumulative Prevalence
Two-week
Sampling
No. + visits
for
individuals/
No. individual
visits
% 95% CI No.
individuals
+ for at least
one visit/No.
individuals
% 95% CI No. + test
results/No.
Tests
% 95% CI No. Infections
positive for
at least one
visit/No.
infections
tested
% 95% CI
646/1434 45.00 42.3, 47.6 92/112 82.10 73.7, 88.7 1549/53053 2.90 2.7, 3.1 386/4144 9.30 8.4, 10.2
Six-month
Sampling
No. + visits
for
individuals/
No. individual
visits
% 95% CI No. i
ndividuals
+ for at least
one visit/No.
individuals
% 95% CI No. positive
test
results/No.
Tests
% 95% CI No. Infections
positive for
at least one
visit/No.
infections
tested
% 95% CI
96/203 47.30 40.2 54.4 59/112 52.70 43.0, 62.2 227/7509 3.00 2.6, 3.5 158/4144 3.80 3.2, 4.4
The point prevalence represents the average point prevalence at each visit weighted by the number of observations at each visit. Cumulative prevalence accounts for
all individuals or infections that were HPV positive at visits 1 through 14 (two-week interval) or visits 1 through 14 (six-month interval).
1A total of 5 individuals were missing a single HPV type for one visit.
CI = confidence interval.
doi:10.1371/journal.pone.0011918.t002
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We evaluated the relationship between HPV viral load and
persistence or clearance of five high-risk HPV types (HPV16, 18,
31, 33, or 35). The pattern of viral load over the course of the
study for those individuals with at least one positive line blot assay
for a specific high-risk HPV type is shown in Figure 4. Upon visual
inspection, infections present across multiple visits appeared to
have a higher viral load (Figure 4, darker intensity bars) than those
inconsistently present over time (Figure 4, lighter intensity bars).
This visual impression was statistically confirmed in a transition
analysis that evaluated whether the odds of a positive oral HPV
test at a given visit was affected by the HPV viral load at the prior
visit (Table 4). For each HPV type evaluated, the odds of a positive
test were significantly increased among individuals who tested
positive at the previous visit. Additionally, there was a significant
increase in the odds of a HPV-positive test for each unit increase in
adjusted HPV copy number from the previous visit (OR range for
HPV 16, 18, 33, 35: 1.26–1.51, P-values range: ,0.0001–0.0001).
Table 3. The average point prevalence, cumulative prevalence and percentage of all detected infections in visits 1 through 14,
stratified by HPV risk category.
AVERAGE POINT PREVALENCE CUMULATIVE PREVALENCE PROPORTION OF ALL INFECTIONS
No. + Tests/No.
Tests % 95% CI
No. infections + for
at least one visit/No.
infections tested % 95% CI
No. HPV Type X /No.
HPV infections
detected % 95% CI
High Risk HPV Types 878/25811 3.4 3.1, 3.6 219/2016 10.9 9.5, 12.3 219/386 56.7 51.6, 61.8
HPV 16 84/1434 5.9 4.6, 7.2 24/112 21.4 14.2, 30.2 24/386 6.2 4.0, 9.1
HPV 18 38/1434 2.6 1.8, 3.6 23/112 20.5 13.4, 29.2 23/386 6.0 3.8, 8.8
HPV 31 10/1434 0.7 0.3, 1.3 4/112 3.6 0.9, 8.9 4/386 1.0 0.2, 2.6
HPV 33 22/1434 1.5 0.9, 2.3 7/112 6.3 2.5, 12.5 7/386 1.8 0.7, 3.7
HPV 35 92/1434 6.4 5.2, 7.8 23/112 20.5 13.4, 29.2 23/386 6.0 3.8, 8.8
Low Risk HPV Types 671/27242 2.5 2.2, 2.7 167/2128 7.8 6.7, 9.1 167/386 43.3 38.2, 48.4
doi:10.1371/journal.pone.0011918.t003
Figure 2. The relationship between type-specific oral HPV infections detected at two-week and six-month sampling intervals. The
flow chart shows the relationship between oral HPV infections detected at a six-month sampling interval (visits 1 and 14, above the horizontal line)
and categorized as persistent (+/+), cleared (+/2), newly detected (2/+), or absent (2/2) and their categorization as persistent (P), transient (T), or
absent (A) infections under the two-week interval definitions (see methods). Persistent infections under the two-week categorization that
subsequently cleared (C) are also indicated. However, cleared infections which recurred are not included in the figure, refer to text. A summary of
infections as categorized under a two-week sampling interval as persistent, transient, absent (A) and cleared is included below the horizontal line.A
total of 3365 possible infections were evaluated at visits 1 and 14 ((91637) 22).
doi:10.1371/journal.pone.0011918.g002
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the six-month interval sampling (visits 1 and 14) and baseline
characteristics (age, gender, smoking, CD4 count, viral load, and
HPV serostatus) did not show any significant associations (data not
shown).
Discussion
Our data indicate a very low probability of interval detection of
a type-specific oral HPV infection if the type was not detected at a
six-month sampling interval. Furthermore, there was a very high
probability that a type-specific infection categorized as persistent
at a six-month sampling interval was detectable for the majority of
the intervening two-week visits. A six-month sampling interval
therefore appears appropriate for natural history studies of oral
HPV infection that model factors associated with type-specific
persistence.
Cervical HPV natural history studies serve as a model for
development of analogous studies at other anatomic sites (e.g. oral
and anal). The clinical algorithm for cervical cancer screening
predated natural history studies of cervical HPV infection and
predetermined the commonly used six-month sampling interval.
Shorter sampling intervals were not examined prior to implemen-
tation of large, well-designed landmark natural history studies.
The expense, complexity and burden of serial anogenital sampling
likely prohibited more frequent sampling. Consequently, cervical
infections that would be detected at a shorter interval are generally
believed to not be pathologically significant, while persistence of
infection at six-month intervals significantly elevates risk for
cervical dysplasia[13] and thus has been established as a surrogate
for this disease outcome [14]. Given the growing recognition of
oral HPV infection as a risk factor for oral cancers, we elected to
examine a priori the potential biases introduced by sampling
interval, rather than to assume the cervical standard of a six-
month sampling interval.
Our initial studies of the natural history of oral HPV infection
have focused on a study population with high prevalence, HIV-
infected individuals. We acknowledge that the behavior of
infections in this population likely differs from what would be
observed in an immunocompetent population. For example,
transient detection of oral HPV infection was commonly observed
with two-week sampling, and the underlying reasons for this
observation are unclear. This may be attributable to technical
issues, such as variability in factors affecting oral rinse sampling
over time, or fluctuation of HPV viral load above and below the
lower limit of detection of the Roche line blot, which is known to
vary by type. Consistent with such fluctuation around the limit of
assay sensitivity is our finding that the majority of cleared
infections under the two-week definition subsequently recurred
and met criteria for persistence. Although laboratory contamina-
Figure 3. Probability of type-specific oral HPV infection detection depending upon the proportion of the two-week visits that an
infection was detected, stratified by six-month categorization as persistent, absent, cleared or newly detected infection. For each six
month interval categorization of oral HPV type-specific infection status (+/+, 2/2, +/2, 2/+), the probability of observing a positive test result for a
fixed proportion of two week interval visits or greater is plotted as a function of the proportion of two-week interval visits (P). The vertical grey line
highlights the case in which at least half of the visits are positive, P=0.5 (see results text).
doi:10.1371/journal.pone.0011918.g003
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observe any evidence of contamination in control samples.
Alternatively, in an immunosuppressed population the high
frequency of transient, low viral load infection may represent
intermittent reactivation of infections due to immunosuppression.
Transient detection may also represent exposure in the absence of
subsequent establishment of infection. We did not have the
interval sexual behavior data which may have allowed us to
explore this possibility.
The biological significance of transient HPV infections in the
oral cavity, oropharynxand cervix is unclear. While the majority of
cervical HPV infections are transient infections, persistent
infections are significantly more likely to progress to both
premalignant and malignant lesions[13]. However, even transient
cervical HPV infections (defined as an HPV infection detected at
only one visit within a 3 to 12 month period) have been associated
with an approximate 5-fold (OR 5.5 95%CI 1.4–21.9) increased
risk of squamous intraepithelial lesions in comparison to no
detection[15]. High HPV viral load is also associated with elevated
risk for incident cervical intraepithelial neoplasia 2 (CIN II) or
more invasive pathology[16]. Our two-week interval analysis
suggests that infections with a high HPV viral load were more
likely to persist than low viral load infections, but an important
limitation to this study is that associations with disease outcomes in
the oral cavity were not possible.
Our data lend support to the use of a six-month sampling
interval for studies designed to evaluate factors associated with
type-specific infection persistence. However, misclassification of
Figure 4. Patterns of adjusted HPV viral load (VL) at two-week intervals for individuals positive by line blot for HPV types 16, 18,
31, 33, and 35. White cells and grey cells represent the absence and presence, respectively, of an HPV infection as determined by real-time PCR. The
grey scale indicates ordinal categories of increasing adjusted HPV VL values (from light gray to dark gray). The adjusted HPV VL represents the log of
10
6 times the ratio of HPV copies to ERV-3 copies. Missing VL values are indicated by outlined cells. The blank lines represent 11 infections detected
by line blot assay that were either not detected (10) or had missing data (1) by VL.
doi:10.1371/journal.pone.0011918.g004
Table 4. Odds of detection of a type-specific HPV infection as a function of adjusted HPV viral load (via RT-PCR) at the prior visit.
+ Given Previous 2 + Given Previous + eb P-value ed P-value
(+/2) % 95% CI (+/+) % 95% CI
HPV 16 24/209 11 7, 17 45/70 64 51, 76 14.45 ,0.0001 1.51 ,0.0001
HPV 18 29/209 14 9, 20 18/46 39 25, 55 3.99 0.0001 1.26 0.0001
HPV 31 12/32 38 21, 57 11/21 52 29, 75 1.83 0.2870 1.29 0.1310
HPV 33 11/53 21 10, 35 30/39 76 59, 89 12.30 ,0.0001 1.44 ,0.0001
HPV 35 34/172 20 14, 27 83/117 71 61, 79 9.91 ,0.0001 1.33 ,0.0001
e
brepresents the ratio of the odds of an infection among individuals with and without an infection at the previous visit.
e
drepresents the change in the odds of infection per unit increase of adjusted viral load at the previous visit.
doi:10.1371/journal.pone.0011918.t004
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overestimation of the median time to clearance of incident oral
HPV infections. A further limitation is that HPV viral load was
measured only among individuals with at least one positive line
blot assay of the corresponding HPV type. Low copy number oral
HPV infections below the lower limit of sensitivity of the line blot
would not be selected. As these low copy number infections would
be expected to have a higher clearance rate than high copy
number HPV infection, we may have underestimate the
association between viral load and persistence.
Oral HPV prevalence in the study population appeared to be a
reasonable approximation of the proportion infected over time.
However, it is important to note the potential effect of missing
data, which may have caused us to underestimate cumulative
prevalence. The difference in cumulative prevalence estimates at
two-week and six-month sampling intervals indicate that a six-
month interval sampling may significantly underestimate the
proportion of the study population that has been ‘‘exposed’’ and
misclassify individuals as ‘‘unexposed’’. Therefore, a six-month
sampling interval may bias point estimates for factors that increase
risk of acquiring an oral HPV infection toward the null.
Despite these limitations, this is the first short term natural
history study of oral HPV infection and the first to report results
on more than two consecutive visits. Based upon this data, a six-
month sampling interval is currently being used in our natural
history studies of oral HPV infection to evaluate factors affecting
type-specific oral HPV persistence.
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